Loading
A phase 3 trial of Savolitinib, Durvalumab, Sunitinib in renal cell carcinoma, run by AstraZeneca, active and no longer recruiting.
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC is a phase 3 interventional study registered as NCT05043090 by AstraZeneca, with 148 participants enrolled, started 2021-10-28 and due to reach its primary completion in 2025-12-31. Interventions recorded: savolitinib, durvalumab, sunitinib. Conditions listed: Papillary Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PRCC, Savolitinib, Papillary renal cell carcinoma, Sunitinib.
Shares Savolitinib, Durvalumab, AstraZeneca, Small-molecule kinase inhibitors.
Shares Savolitinib, Papillary renal cell carcinoma, Sunitinib, Anti-angiogenic therapy.
Shares Durvalumab, Anti-angiogenic therapy, AstraZeneca, Small-molecule kinase inhibitors.
Shares Savolitinib, Papillary renal cell carcinoma, Sunitinib.
Shares Sunitinib, Anti-angiogenic therapy, Renal cell carcinoma, Small-molecule kinase inhibitors.
Shares Durvalumab, Anti-angiogenic therapy, AstraZeneca, Immune checkpoint inhibitors.
Shares Sunitinib, Anti-angiogenic therapy, Renal cell carcinoma, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/